Physiomics PLC
LSE:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Physiomics PLC
Free Cash Flow
Physiomics PLC
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Physiomics PLC
LSE:PYC
|
Free Cash Flow
-£470k
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-2%
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Free Cash Flow
-£116.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Free Cash Flow
-£4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Free Cash Flow
-£3.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Free Cash Flow
-£1.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Free Cash Flow
-£15.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-22%
|
|
Physiomics PLC
Glance View
Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. The company is headquartered in Oxford, Oxfordshire and currently employs 7 full-time employees. The company went IPO on 2004-12-20. The firm offer Virtual Tumour technology and other tools to predict the effects of cancer treatments. The Company’s Virtual Tumour software platform is used to simulate the effects of anti-cancer agents on pre-clinical and human tumors. The company is used by companies ranging from startup biotech to global large-cap pharmaceuticals. The firm provides a range of Pharmacokinetic/Pharmacodynamics (PK/PD) services, usually in support of smaller companies where this function is outsourced. The Company’s services include oncology specialists, mechanistic modelling, PK/PD, quantitative systems pharmacology and mathematical modelling.
See Also
What is Physiomics PLC's Free Cash Flow?
Free Cash Flow
-470k
GBP
Based on the financial report for Dec 31, 2025, Physiomics PLC's Free Cash Flow amounts to -470k GBP.
What is Physiomics PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-2%
Over the last year, the Free Cash Flow growth was 6%. The average annual Free Cash Flow growth rates for Physiomics PLC have been -16% over the past three years , -39% over the past five years , and -2% over the past ten years .
